E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE |
|
E.1.1.1 | Medical condition in easily understood language |
advanced or repeating non small cell lung cancer for those patients that have not received chemotherapy for the advanced form of the disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025054 |
E.1.2 | Term | Lung cancer non-small cell stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025052 |
E.1.2 | Term | Lung cancer non-small cell stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025048 |
E.1.2 | Term | Lung cancer non-small cell recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025051 |
E.1.2 | Term | Lung cancer non-small cell stage II |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025046 |
E.1.2 | Term | Lung cancer cell type unspecified stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025055 |
E.1.2 | Term | Lung cancer non-small cell stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025053 |
E.1.2 | Term | Lung cancer non-small cell stage IIIA |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025050 |
E.1.2 | Term | Lung cancer non-small cell stage I |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of MEGF0444A used in combination with carboplatin + paclitaxel + bevacizumab therapy in patients with advanced or recurrent non-squamous NSCLC, as measured by progression-free survival |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of MEGF0444A in combination with paclitaxel + carboplatin + bevacizumab therapy in patients with advanced or recurrent non-squamous NSCLC • To evaluate the efficacy of MEGF0444A in combination with paclitaxel + carboplatin + bevacizumab therapy in patients with advanced or recurrent non-squamous NSCLC, as measured by objective response rate, duration of objective response and overall survival • To characterize the PK of MEGF0444A, and the PK of bevacizumab, carboplatin, and paclitaxel and its major metabolite (6α-hydroxypaclitaxel) when combined with MEGF0444A • To compare the delay in deterioration of disease-related symptoms, to show impact of MEGF0444A on global health status/Quality of Life and to evaluate treatment-related symptoms as measured by the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the lung module (QLQ-LC13) |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
DNA REPOSITORY SUBSTUDY IN ASSOCIATION WITH MEGF0444A STUDY MEF4984g PROTOCOL NUMBER: MEF4984g (DNA Substudy) Version of Protcol:FINAL Date of Protocol : 4 April 2011
The primary objective of this study is to perform exploratory analyses to generate hypotheses identifying genes associated with treatment response, toxicity, or disease risk. If such genetic hypotheses are identified, they may be tested in future clinical studies within this therapeutic area. |
|
E.3 | Principal inclusion criteria |
Patients must meet the following criteria to be eligible for study entry: • Signed informed consent form • Age ≥ 18 years • Able to comply with the protocol • Histologically or cytologically documented inoperable (Stage IV) or recurrent non-squamous NSCLC. Diagnoses of non-squamous NSCLC that are based on sputum cytology alone are not acceptable. Mixed tumors should be categorized according to the predominant cell type. • ECOG performance status of 0 or 1 (see Appendix E) • Life expectancy >12 weeks • Measurable disease, as defined by RECIST 1.1 (see Appendix C) • Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment: Absolute neutrophil count (ANC) ≥ 1500 cells/μL (without granulocyte colony-stimulating factor support within 2 weeks prior to randomization) Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to randomization) Hemoglobin ≥ 9.0 g/dL Patients may be transfused or receive erythropoietic treatment to meet this criterion. AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions: Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN Patients with documented liver or bone metastases:alkaline phosphatase ≤ 5 × ULN, Serum bilirubin <1.5x ULN, Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may be enrolled. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN within 7 days prior to starting study treatment Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min on the basis of the Cockroft−Gault glomerular filtration rate estimation: (140 − age) × (weight in kg) × (0.85 if female) 72 × (serum creatinine in mg/dL) Urine dipstick for proteinuria < 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours. • For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for 6 months after the last dose of bevacizumab or MEGF0444A/placebo • Negative serum pregnancy test within 7 days of starting study treatment in premenopausal women and women < 2 years after the onset of menopause
|
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following criteria will be excluded from study entry: a. General Medical Exclusions • Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy or investigational therapy) before Day 1 of Cycle 1 for the treatment of Stage IV or recurrent NSCLC Patients who received prior adjuvant chemotherapy or radiotherapy for NSCLC are not excluded if the time interval from completion of adjuvant therapy until disease progression is > 12 months. Patients who received prior palliative radiotherapy for bone metastases are not excluded (if >1 week prior to Day 1 of Cycle 1). Patients who receive hormone-replacement therapy or oral contraceptives are not excluded Patients who received herbal therapy ≥ 2 weeks prior to Day 1 are not excluded • Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment • Malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent • Symptomatic or uncontrolled hypercalcemia requiring continued use of bisphosphonate therapy Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinical significant hypercalcemia are eligible. Uncontrolled hypercalcemia (Ca > 12 mg/dL or >1.5 ionized calcium) • Pregnant and lactating women • Known hypersensitivity to Chinese hamster ovary cell products, recombinant human antibodies or any of the chemotherapy agents to be used in this study • Any disorder that compromises the ability of the patient to provide written informed consent and/or to comply with study procedures • Leptomeningeal disease • Active infection requiring IV antibiotics • Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs, inhaled corticosteroids, or the equivalent of ≤ 10 mg/day prednisone • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, or cirrhosis • Grade ≥ 2 peripheral neuropathy • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk for treatment complications
For Bevacizumab-Specific Exclusions please see study protocol |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint of this study is Progression Free Survival (PFS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients will undergo tumor assessment at baseline, after every 2 cycles and at treatment completion/early termination. |
|
E.5.2 | Secondary end point(s) |
Secondary Efficacy Endpoints
Overall Response (OR) and Overall Survival (OS)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
For Overall Response (OR) Patients will undergo tumor assessment at baseline, after every 2 cycles and at treatment completion/early termination
For Overall Survival (OS) Survival follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months until death, loss to follow-up, or study termination by Genentech. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Czech Republic |
France |
Hungary |
Poland |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |